Terada T, Fujimoto K, Nomura M, Yamashita J, Wierzba K, Yamazaki R, Shibata J, Sugimoto Y, Yamada Y, Kobunai T
Hanno Research Center, Taiho Pharmaceutical Co., Ltd., Saitama, Japan.
J Med Chem. 1993 Jun 11;36(12):1689-99. doi: 10.1021/jm00064a002.
A series of 4 beta-alkyl (7-10), 4 beta-aminoalkyl (12a-y), and 4 beta-amidoalkyl derivatives (14a-g) of 4'-O-demethyl-4-desoxypodophyllotoxin have been synthesized, and their cytotoxicity, inhibition of DNA topoisomerase II (Topo II), and tubulin polymerization were evaluated. All derivatives of 12a-y and 14a-g did not inhibit tubulin polymerization. Many compounds exhibited cytotoxicity and inhibition of Topo II. In particular, 12o, 12s, 12t, and 12u strongly inhibited Topo II (IC50 (microM) 32.5, 60.9, 58.8, and 33.6, respectively) and were strong cytotoxicity against P388 cells (IC50 (M) 1.0, 4.1, 3.3, and 3.0 x 10(-9), respectively), compared with VP-16 (IC50 (microM) 59.2, IC50 (M) 1 x 10(-8), respectively). These compounds were nearly equal to or superior to VP-16 in antitumor activity in vivo (L1210, P388, and Lewis lung) and were more cytotoxic against various human cell lines in vitro than VP-16.
合成了一系列4'-O-去甲基-4-脱氧鬼臼毒素的4-β-烷基(7-10)、4-β-氨基烷基(12a-y)和4-β-酰胺基烷基衍生物(14a-g),并评估了它们的细胞毒性、对DNA拓扑异构酶II(Topo II)的抑制作用以及微管蛋白聚合作用。12a-y和14a-g的所有衍生物均未抑制微管蛋白聚合。许多化合物表现出细胞毒性和对Topo II的抑制作用。特别是,12o、12s、12t和12u强烈抑制Topo II(IC50(μM)分别为32.5、60.9、58.8和33.6),并且对P388细胞具有很强的细胞毒性(IC50(M)分别为1.0、4.1、3.3和3.0×10⁻⁹),与VP-16(IC50(μM)59.2,IC50(M)1×10⁻⁸)相比。这些化合物在体内抗肿瘤活性(L1210、P388和Lewis肺癌)方面几乎与VP-16相当或优于VP-16,并且在体外对各种人类细胞系的细胞毒性比VP-16更强。